$63.48
0.00%
NYSE, Thu, Dec 26 2024
ISIN
US1488061029
Symbol
CTLT
Sector
Industry

Catalent Inc Stock price

$63.48
+2.73 4.49% 1M
+7.32 13.03% 6M
+18.55 41.29% YTD
+18.23 40.29% 1Y
-62.88 49.76% 3Y
+7.26 12.91% 5Y
+34.99 122.82% 10Y
NYSE, Closing price Thu, Dec 26 2024
+0.00 0.00%
ISIN
US1488061029
Symbol
CTLT
Sector
Industry

Key metrics

Market capitalization $11.52b
Enterprise Value $16.13b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 162.97
EV/Sales (TTM) EV/Sales 3.65
P/S ratio (TTM) P/S ratio 2.61
P/B ratio (TTM) P/B ratio 3.25
Revenue growth (TTM) Revenue growth 4.39%
Revenue (TTM) Revenue $4.42b
EBIT (operating result TTM) EBIT $155.00m
Free Cash Flow (TTM) Free Cash Flow $99.00m
Cash position $335.00m
EPS (TTM) EPS $-2.27
P/E forward 160.15
P/S forward 2.46
EV/Sales forward 3.44
Short interest 9.16%
Show more

Is Catalent Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,885 stocks worldwide.

Catalent Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Catalent Inc forecast:

4x Hold
100%

Analyst Opinions

4 Analysts have issued a Catalent Inc forecast:

Hold
100%

Financial data from Catalent Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
4,422 4,422
4% 4%
100%
- Direct Costs 3,457 3,457
6% 6%
78%
965 965
1% 1%
22%
- Selling and Administrative Expenses 303 303
8% 8%
7%
- Research and Development Expense 17 17
0% 0%
0%
645 645
4% 4%
15%
- Depreciation and Amortization 490 490
13% 13%
11%
EBIT (Operating Income) EBIT 155 155
18% 18%
4%
Net Profit -413 -413
58% 58%
-9%

In millions USD.

Don't miss a Thing! We will send you all news about Catalent Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Catalent Inc Stock News

Neutral
PRNewsWire
9 days ago
NEW YORK , Dec. 18, 2024 /PRNewswire/ -- S&P MidCap 400 constituent Lennox International Inc. (NYSE: LII) will replace Catalent Inc. (NYSE: CTLT) in the S&P 500, and BILL Holdings Inc. (NYSE: BILL) will replace Lennox International in the S&P MidCap 400 effective prior to the opening of trading on Monday, December 23. Novo Holdings A/S has acquired Catalent in a deal that closed today, December...
Neutral
Reuters
9 days ago
Novo Holdings has completed its $16.5 billion takeover of Catalent , the contract drug manufacturer announced on Wednesday, days after the companies said all regulatory closing conditions were fulfilled.
Positive
Reuters
13 days ago
All regulatory closing conditions related to Novo Holdings' $16.5 billion acquisition of U.S. contract drug maker Catalent had been fulfilled, the companies said on Saturday, adding that the transaction is expected to be completed in the coming days.
More Catalent Inc News

Company Profile

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. It operates through the following segments: Softgel Technologies; Biologics and Specialty Drug Delivery; Oral Drug Delivery; and Clinical Supply Services. The Softgel Technologies segment formulate, develop, and manufacture services for soft capsules. The Biologics and Specialty Drug Delivery segment develops and manufacture services for blow-fill-seal unit doses, prefilled syringes, vials, and cartridges; analytical development and testing services for large molecules; inhaled products for delivery via metered dose inhalers, dry powder inhalers, and intra-nasal sprays. The Oral Drug Delivery segment focuses in the formulation development and manufacturing technologies, and related solutions including: clinical development and commercial manufacturing of a range of oral dose forms, including proprietary fast-dissolve Zydis tablets and both conventional immediate and controlled release tablets, capsules, and sachet products. The Clinical Supply Services segment includes packaging, labeling, storage, distribution, and inventory management for drugs and biologics in clinical trials. The company was founded in April 2007 and is headquartered in Somerset, NJ.

Head office United States
CEO Alessandro Maselli
Employees 16,900
Founded 1933
Website www.catalent.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today